Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
EVZIO (AUTOINJECTOR) vs OFIRMEV
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Competitive antagonist at mu-opioid receptors, reversing opioid-induced respiratory depression and other central nervous system depressant effects.
OFIRMEV (acetaminophen) is a para-aminophenol derivative with analgesic and antipyretic activity. Its mechanism of action is not fully understood, but it is thought to involve inhibition of cyclooxygenase (COX) enzymes in the central nervous system, with minimal peripheral COX inhibition. It may also act on serotonergic pathways and cannabinoid receptors.
Emergency treatment of known or suspected opioid overdose, manifested by respiratory and/or central nervous system depression
Management of mild to moderate pain,Management of moderate to severe pain with adjunctive opioid analgesics,Reduction of fever
Adults: 2 mg intramuscularly or subcutaneously into the anterolateral thigh, repeat every 2-3 minutes as needed until emergency medical assistance arrives.
IV: 1000 mg every 6 hours or 650 mg every 4 hours; maximum single dose: 1000 mg; minimum dosing interval: 4 hours; maximum daily dose: 4000 mg.
Terminal elimination half-life of naloxone is approximately 1–2 hours in adults. The short half-life results in a duration of action that may be shorter than that of the opioid (e.g., fentanyl, methadone), necessitating repeated doses or continuous infusion. In neonates, half-life is prolonged (3–4 hours).
Terminal elimination half-life is 2-3 hours in adults (2.5-3 hours in children). Clinically, dosing every 4-6 hours is needed to maintain therapeutic levels.
Primarily hepatic via glucuronidation; minor pathways include N-dealkylation. CYP450 involvement is minimal.
Acetaminophen is primarily metabolized in the liver via conjugation with glucuronide (50-60%) and sulfate (20-30%). A minor amount is oxidized by cytochrome P450 (CYP2E1, CYP1A2, CYP3A4) to a toxic reactive metabolite (NAPQI), which is normally detoxified by glutathione. At toxic doses, glutathione is depleted, leading to NAPQI accumulation and hepatotoxicity.
Naloxone is primarily metabolized in the liver via glucuronidation, with minor contributions from N-dealkylation. The metabolites (naloxone-3-glucuronide) and parent drug are excreted renally. Approximately 50% of a dose is excreted in urine as naloxone-3-glucuronide, 25% as unchanged naloxone (after IV), and <5% in feces. Biliary excretion is minimal (<1%).
Primarily renal (85% as sulfate and glucuronide conjugates, 10% as unchanged drug). Less than 5% fecal/biliary.
Approximately 45% bound to plasma proteins, primarily albumin.
10-25% bound to albumin at therapeutic concentrations.
2–3 L/kg in adults. The large Vd indicates extensive tissue distribution, including crossing the blood-brain barrier rapidly to reverse central opioid effects. In neonates, Vd is higher (3–5 L/kg).
0.8-1.0 L/kg. Indicates distribution into total body water.
Intramuscular or subcutaneous: approximately 60–80% relative to IV (with the autoinjector delivering 0.4 mg or 2 mg doses). Oral bioavailability is <2% due to extensive first-pass metabolism, making oral administration ineffective for opioid reversal; thus, the autoinjector is for IM/SC use only.
100% (intravenous); not applicable for other routes as OFIRMEV is IV only.
No dose adjustment required for renal impairment.
No dose adjustment required for GFR ≥30 m L/min. For GFR <30 m L/min, extend dosing interval to every 8 hours; maximum daily dose 3000 mg.
No dose adjustment required for hepatic impairment.
Child-Pugh Class A: No adjustment. Child-Pugh Class B: Reduce total daily dose by 50% (max 2000 mg/day). Child-Pugh Class C: Contraindicated or use with extreme caution; reduce dose to 50% of standard and extend interval to every 8 hours; maximum 2000 mg/day.
Weight-based dosing: For children weighing <20 kg, 0.1 mg/kg intramuscularly or subcutaneously; for ≥20 kg, 2 mg intramuscularly or subcutaneously. Repeat every 2-3 minutes as needed.
Weight-based: <10 kg: 7.5 mg/kg/dose every 6 hours; 10-50 kg: 15 mg/kg/dose every 6 hours; >50 kg: 1000 mg every 6 hours or 650 mg every 4 hours. Maximum single dose: 15 mg/kg (up to 1000 mg); maximum daily dose: 75 mg/kg (up to 4000 mg).
No specific dose adjustment needed; use caution due to potential comorbidities.
No specific dose adjustment; consider reduced renal function. For Cr Cl <30 m L/min, extend interval to every 8 hours. Maximum daily dose: 3000 mg in frail elderly or with comorbidities.
None.
Acetaminophen has been associated with cases of acute liver failure, at times resulting in liver transplant and death. Most of the cases of liver injury are associated with the use of acetaminophen at doses that exceed 4000 mg per day, and often involve more than one acetaminophen-containing product.
Risk of acute withdrawal syndrome in opioid-dependent patients.,May precipitate severe withdrawal in neonates if used during pregnancy.,Limited efficacy against buprenorphine or partial agonists; higher or repeat doses may be needed.,Monitor for recurrence of respiratory depression due to short duration of action relative to some opioids.,Not a substitute for emergency medical care.
Risk of serious hepatotoxicity, especially with doses >4000 mg/day or in patients with underlying liver disease,Risk of severe skin reactions (Stevens-Johnson syndrome, toxic epidermal necrolysis, acute generalized exanthematous pustulosis) – discontinue at first sign of rash,Risk of hypersensitivity reactions including anaphylaxis,Use caution in patients with severe hepatic impairment, active hepatic disease, or alcoholism,Avoid concurrent use of other acetaminophen-containing products
Hypersensitivity to naloxone or any component of the autoinjector.
Known hypersensitivity to acetaminophen or any component of the formulation,Severe hepatic impairment or active liver disease (relative contraindication without black box)
No known food interactions with naloxone. No dietary restrictions required.
No known food interactions. However, avoid excessive alcohol consumption as it may increase the risk of liver damage.
Naloxone crosses the placenta. First trimester: No evidence of teratogenicity in animal studies at doses up to 100 mg/kg/day (SC). Second/third trimester: No known risk of fetal malformations; may precipitate withdrawal in opioid-dependent fetuses, potentially causing fetal distress or preterm labor.
Acetaminophen (OFIRMEV) is generally considered low risk across all trimesters. No increased risk of major congenital anomalies has been consistently demonstrated. Chronic high-dose use in third trimester may be associated with preterm birth or low birth weight. Avoid prolonged use above recommended doses.
Naloxone is excreted in breast milk in trace amounts; no adverse effects reported in nursing infants. M/P ratio not available.
Acetaminophen is excreted in breast milk in low concentrations (M/P ratio approximately 0.9-1.0). Considered compatible with breastfeeding; peak milk levels occur 1-2 hours after maternal dosing. Use lowest effective dose for shortest duration.
No pharmacokinetic data indicate dose adjustments; use same dose as non-pregnant adults. Reversal of opioid effects may precipitate withdrawal; monitor closely.
No dose adjustment required during pregnancy. Pharmacokinetic changes in pregnancy (increased volume of distribution, clearance) may lead to lower peak concentrations but standard dosing remains effective. Maximum single dose: 1 g; maximum daily dose: 4 g.
EVZIO is a naloxone auto-injector for emergency treatment of opioid overdose. Administer intramuscularly or subcutaneously into anterolateral thigh (through clothing if necessary). Each device delivers a single 2 mg dose. After use, seek immediate medical attention due to short half-life (30-81 min) relative to opioids; repeated doses may be needed. Monitor for opioid withdrawal syndrome, especially in physically dependent patients. Store at 20-25°C (68-77°F), excursions permitted to 15-30°C (59-86°F). Do not remove the auto-injector from its case until ready to use.
OFIRMEV (acetaminophen) injection is an IV formulation of acetaminophen used for pain and fever management. It is a prodrug that requires no hepatic conversion, providing rapid onset of action. Monitor for hepatotoxicity; maximum daily dose is 4 grams in adults but lower in patients with hepatic impairment or malnutrition. Do not exceed 1 gram per dose. Hypotension and anaphylaxis have been reported. Not interchangeable with oral acetaminophen due to dose equivalency. Use with caution in patients with alcohol use disorder.
Inject EVZIO into the outer thigh, through clothing if needed, as soon as overdose is suspected.,After injecting, call 911 or seek emergency medical help immediately.,The effect of EVZIO lasts only 30-90 minutes; opioids may last longer, so repeated doses might be necessary.,Family and caregivers should receive training on recognizing overdose signs (unconsciousness, slow breathing, pinpoint pupils) and using EVZIO.,Store EVZIO in its case at room temperature, away from light and moisture; do not refrigerate or freeze.,Check expiration date regularly and replace before expiry; training devices are for practice only.,An overdose may cause withdrawal symptoms such as nausea, vomiting, sweating, rapid heart rate, or agitation.
OFIRMEV is given intravenously for pain or fever.,Do not take additional acetaminophen-containing medications while receiving OFIRMEV.,Report any signs of allergic reaction (rash, itching, swelling, trouble breathing).,Seek immediate medical attention if you experience severe abdominal pain, yellowing of skin or eyes, or dark urine.,Inform your healthcare provider about all medications you are taking, especially blood thinners.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about EVZIO (AUTOINJECTOR) vs OFIRMEV, answered by our medical review team.
EVZIO (AUTOINJECTOR) is a Opioid Antagonist that works by Competitive antagonist at mu-opioid receptors, reversing opioid-induced respiratory depression and other central nervous system depressant effects.. OFIRMEV is a Non-opioid Analgesic that works by OFIRMEV (acetaminophen) is a para-aminophenol derivative with analgesic and antipyretic activity. Its mechanism of action is not fully understood, but it is thought to involve inhibition of cyclooxygenase (COX) enzymes in the central nervous system, with minimal peripheral COX inhibition. It may also act on serotonergic pathways and cannabinoid receptors.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between EVZIO (AUTOINJECTOR) and OFIRMEV depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of EVZIO (AUTOINJECTOR) is: Adults: 2 mg intramuscularly or subcutaneously into the anterolateral thigh, repeat every 2-3 minutes as needed until emergency medical assistance arrives.. The standard adult dose of OFIRMEV is: IV: 1000 mg every 6 hours or 650 mg every 4 hours; maximum single dose: 1000 mg; minimum dosing interval: 4 hours; maximum daily dose: 4000 mg.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between EVZIO (AUTOINJECTOR) and OFIRMEV in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. EVZIO (AUTOINJECTOR) is classified as Category C. Naloxone crosses the placenta. First trimester: No evidence of teratogenicity in animal studies at doses up to 100 mg/kg/day (SC). Second/third trimester: No known risk of fetal ma. OFIRMEV is classified as Category C. Acetaminophen (OFIRMEV) is generally considered low risk across all trimesters. No increased risk of major congenital anomalies has been consistently demonstrated. Chronic high-dos. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.